Recombinant human erythropoietin-Fc fusion protein (Dongguan baolijian Biotech)
重组人红细胞生成素（Fc）融合蛋白（东莞宝丽健生物工程）
Report date: 2022/01/17 12:14:22
Base Information
Drug NameRecombinant human erythropoietin-Fc fusion protein (Dongguan baolijian Biotech)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesDongguan Baolijian Bioengineering Research And Development Co LtdDongguan Taili Biological Engineering Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesDongguan Baolijian Bioengineering Research And Development Co LtdDongguan Taili Biological Engineering Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A